Sunshine Financial Statements From 2010 to 2025

SBFMW Stock  USD 0.20  0.01  4.76%   
Sunshine Biopharma financial statements provide useful quarterly and yearly information to potential Sunshine Biopharma Warrant investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Sunshine Biopharma financial statements helps investors assess Sunshine Biopharma's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Sunshine Biopharma's valuation are summarized below:
Gross Profit
10.1 M
Profit Margin
(0.13)
Revenue
33 M
Earnings Share
(2.21)
Quarterly Revenue Growth
0.416
There are over one hundred nineteen available fundamental trend indicators for Sunshine Biopharma Warrant, which can be analyzed over time and compared to other ratios. All traders should should double-check Sunshine Biopharma's current fundamental trends against the trends from 2010 to 2025 to make sure the company is sustainable.

Sunshine Biopharma Total Revenue

29.09 Million

Check Sunshine Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sunshine Biopharma's main balance sheet or income statement drivers, such as Interest Expense of 148.9 K, Other Operating Expenses of 34.9 M or Total Operating Expenses of 15.8 M, as well as many indicators such as Price To Sales Ratio of 0.3, Dividend Yield of 0.0 or PTB Ratio of 0.34. Sunshine financial statements analysis is a perfect complement when working with Sunshine Biopharma Valuation or Volatility modules.
  
Check out the analysis of Sunshine Biopharma Correlation against competitors.
For more information on how to buy Sunshine Stock please use our How to Invest in Sunshine Biopharma guide.

Sunshine Biopharma Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets33 M31.4 M7.9 M
Slightly volatile
Total Current Liabilities6.7 M6.4 MM
Slightly volatile
Accounts Payable3.1 MM752.2 K
Slightly volatile
Cash19.7 M18.7 MM
Slightly volatile
Cash And Short Term Investments19.7 M18.7 MM
Slightly volatile
Common Stock Shares Outstanding26.5 K14 K26.6 K
Pretty Stable
Liabilities And Stockholders Equity33 M31.4 M7.9 M
Slightly volatile
Non Current Liabilities Total480.3 K675.9 K533.2 K
Slightly volatile
Other Stockholder Equity101.9 M97 M31.1 M
Slightly volatile
Total Liabilities7.4 M7.1 M2.3 M
Slightly volatile
Total Current Assets30.1 M28.6 M7.2 M
Slightly volatile
Common Stock30.6 K32.2 K169.6 K
Very volatile
Short and Long Term Debt TotalM756.4 K938.8 K
Slightly volatile
Other Assets97 K92.3 K77.1 K
Slightly volatile
Other Current Assets375 K357.2 K90.8 K
Slightly volatile
Short Term Debt129.6 K136.5 K694.8 K
Slightly volatile
Property Plant And Equipment Net1.2 M1.2 M310.9 K
Slightly volatile
Non Current Assets TotalM2.8 M939.8 K
Slightly volatile
Net Receivables3.1 M2.9 M664.1 K
Slightly volatile
Intangible AssetsM1.7 M829.6 K
Slightly volatile
Property Plant EquipmentK6.4 K38.2 K
Slightly volatile
Current Deferred Revenue192.1 K344.8 K155 K
Slightly volatile
Long Term Debt1.2 M2.2 M846.4 K
Slightly volatile
Good Will532.6 K599.1 K653.2 K
Slightly volatile
Short and Long Term Debt4.4 M4.2 M1.7 M
Slightly volatile
Capital Stock24.8 K26.1 K122.4 K
Slightly volatile
Short Term Investments6.1 K6.8 K7.4 K
Slightly volatile
Property Plant And Equipment Gross1.5 M1.4 M376.9 K
Slightly volatile

Sunshine Biopharma Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Interest Expense148.9 K157.9 K153.7 K
Very volatile
Other Operating Expenses34.9 M33.2 M7.7 M
Slightly volatile
Total Operating Expenses15.8 M15.1 M4.2 M
Slightly volatile
Selling General Administrative12.2 M11.6 M3.4 M
Slightly volatile
Selling And Marketing Expenses886.6 K844.4 K469.5 K
Slightly volatile
Research Development2.2 M2.1 M538.1 K
Slightly volatile
Total Revenue29.1 M27.7 M5.4 M
Slightly volatile
Gross Profit10.1 M9.6 M1.9 M
Slightly volatile
Cost Of Revenue19 M18.1 M3.7 M
Slightly volatile
Reconciled Depreciation151.9 K144.6 K58.3 K
Slightly volatile

Sunshine Biopharma Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Other Non Cash Items3.7 M5.3 M3.4 M
Slightly volatile
Total Cash From Financing Activities3.4 M3.9 M3.7 M
Slightly volatile
End Period Cash Flow19.7 M18.7 MM
Slightly volatile
Begin Period Cash Flow26.4 M25.1 M4.8 M
Slightly volatile
Depreciation180.1 K171.5 K44.3 K
Slightly volatile
Net Borrowings3.4 M3.3 M1.4 M
Slightly volatile
Change To Netincome12.9 M12.3 M4.1 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.30.32174.7 K
Slightly volatile
Days Sales Outstanding42.2444.47270
Slightly volatile
Average Payables2.5 M2.4 MM
Slightly volatile
Stock Based Compensation To Revenue4.394.6227.9964
Slightly volatile
Capex To Depreciation5.776.0857.6685
Slightly volatile
Payables Turnover6.667.0182.8838
Slightly volatile
Sales General And Administrative To Revenue0.460.48172
Slightly volatile
Research And Ddevelopement To Revenue0.08420.08862.2156
Slightly volatile
Capex To Revenue0.03570.0376137
Slightly volatile
Cash Per Share1.3 K1.2 K603
Slightly volatile
Days Payables Outstanding51.2253.91389
Pretty Stable
Income Quality1.841.750.6015
Slightly volatile
Intangibles To Total Assets0.05770.06070.4688
Slightly volatile
Current Ratio6.775.165.6383
Pretty Stable
Receivables Turnover10.3110.8618.7009
Pretty Stable
Graham NumberK3.4 K2.7 K
Slightly volatile
Capex Per Share71.0174.5171
Slightly volatile
Average Receivables2.1 MM757.6 K
Slightly volatile
Revenue Per Share1.9 K1.8 K411
Slightly volatile
Debt To Assets0.02630.02771.724
Pretty Stable
Days Of Payables Outstanding51.2253.91389
Pretty Stable
Ebt Per Ebit0.730.771.9446
Pretty Stable
Quick Ratio6.593.975.3844
Pretty Stable
Net Income Per E B T0.770.991.1731
Slightly volatile
Cash Ratio5.373.374.343
Very volatile
Days Of Sales Outstanding42.2444.47270
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.231.251.316
Slightly volatile
Fixed Asset Turnover22.4821.417.2162
Slightly volatile
Debt Ratio0.02630.02771.724
Pretty Stable
Price Sales Ratio0.30.32174.7 K
Slightly volatile
Asset Turnover0.830.790.2639
Slightly volatile

Sunshine Fundamental Market Drivers

Cash And Short Term Investments16.3 M

About Sunshine Biopharma Financial Statements

Sunshine Biopharma investors use historical fundamental indicators, such as Sunshine Biopharma's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Sunshine Biopharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue344.8 K192.1 K
Total Revenue27.7 M29.1 M
Cost Of Revenue18.1 M19 M
Stock Based Compensation To Revenue 4.62  4.39 
Sales General And Administrative To Revenue 0.48  0.46 
Research And Ddevelopement To Revenue 0.09  0.08 
Capex To Revenue 0.04  0.04 
Revenue Per Share1.8 K1.9 K
Ebit Per Revenue(0.18)(0.19)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Sunshine Stock Analysis

When running Sunshine Biopharma's price analysis, check to measure Sunshine Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sunshine Biopharma is operating at the current time. Most of Sunshine Biopharma's value examination focuses on studying past and present price action to predict the probability of Sunshine Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sunshine Biopharma's price. Additionally, you may evaluate how the addition of Sunshine Biopharma to your portfolios can decrease your overall portfolio volatility.